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Stem Cell Research & Th erapy was launched just over two 
years ago, with the aim of its becoming the major forum 
for basic and translational stem cell research and the 
development of stem cell-based therapies [1]. Stem Cell 
Research & Th erapy is particularly interested in articles 
that bridge the gap between laboratory and clinic. Th ere 
are many challenges in bringing stem cell therapies to the 
clinic in comparison to the translational pathway for 
traditional pharmaceutical products.
Th e beneﬁ ts of open-access publication were reviewed 
in last year’s anniversary editorial [2]. In this editorial, we 
would like to present the recent progress on important 
issues that inﬂ uence an author’s decision on where to 
submit his or her manuscript.
Progress in the last year
MEDLINE
Stem Cell Research & Th erapy is now indexed by 
MEDLINE, the premier bibliographic database of the US 
National Library of Medicine. Each article record is 
indexed by using MeSH (Medical Subject Headings) 
terms, and thus the articles are highly accessible via 
PubMed. Readers can click straight through from 
PubMed to the Stem Cell Research & Th erapy website to 
read the open-access research articles without having to 
register or sign in. Th e ﬁ nal published version of all 
articles is automatically deposited in PubMed Central; 
research articles are publicly available immediately upon 
publication, whereas subscription content, such as 
reviews and commentaries, becomes available a year 
after publication.
Thomson Reuters
Th omson Reuters (formerly the Institute for Scientiﬁ c 
Information) (New York, NY, USA) has accepted Stem 
Cell Research & Th erapy for tracking from volume 1, 
issue 1, and the journal’s ﬁ rst (partial) impact factor is 
expected in the 2011 Journal Citation Report, which is to 
be published this summer. Th e early acceptance of Stem 
Cell Research & Th erapy is an indication of the journal’s 
success in its ﬁ rst few years of existence.
Growth of the journal
Th e journal received over 19,000 article accesses via the 
website in March 2012 and this ﬁ gure has been growing 
each month. Th e two most accessed research articles 
published in 2011 have both received over 5,000 accesses 
so far; Jung Lim and colleagues [3] studied the eﬀ ects of 
mesen chymal stem cells in a rat model of cerebral 
ischemia, and Alan Nixon’s group [4] used fetal-derived 
embryonic-like stem cells to treat tendon injury in 
horses.
A review by editorial board member Christian Jorgen-
sen and colleagues [5] on immunosuppression by mesen-
chymal stem cells remains our all-time most accessed 
article, having received nearly 16,000 accesses in the two 
years since its publication in March 2010.
Articles are regularly featured on the BMC Update, 
which is sent out fortnightly to more than 400,000 
recipients. In addition, registrants on the journal website 
can sign up to receive article alerts on a daily, weekly, 
fortnightly, or monthly basis; new-issue alerts are sent 
out when each issue is complete. Readers can ﬁ nd out 
how many times an article has been accessed or cited via 
the ‘About this article’ link from the right-hand side 
navigation bar, and via the ‘My manuscripts’ section of 
the website, authors can keep track of how many times 
their published articles have been accessed.
Our average time from submission to ﬁ rst decision is 
6  weeks, and the average time from submission to 
publication in 2011 was 20 weeks. We aim to continue to 
improve on this metric in the coming months.
Looking forward
Commissioned articles from opinion leaders in the ﬁ eld 
are a key component of the journal. We aim to increase 
the relevance of this section to translational stem cell 
therapy research in the future. Upcoming commissioned 
content includes reviews from Nicholas Boulis and 
colleagues on stem cell therapy for the spinal cord and 
from Aastrom Biosciences (Ann Arbor, MI, USA) on its 
experience in developing a multicellular therapy ex-
panded from a patient’s own bone marrow. Th ese reviews 
will be published as part of a series on ‘Clinical © 2010 BioMed Central Ltd
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appli cations of stem cells’, edited by Mahendra Rao, a 
member of the editorial board. Also coming up this year 
are a series devoted to ‘Physical inﬂ uences on stem cells’, 
edited by Gordana Vunjak-Novakovic, an editorial board 
member, and a special collection of articles on ‘Stem cell 
research in the Asia-Paciﬁ c region’. Th ese series join our 
published and ongoing series on ‘Induced pluripotent 
stem cells’, ‘Stem cell niche’, ‘Epigenetics and regulation’, 
and ‘Immunology and stem cells’ as references within the 
ﬁ eld [6].
Our key objectives over the next few years are to 
increase the international reach and impact of the journal 
and to seek new and eﬀ ective ways of engaging and 
communicating with our readers and contributors. Please 
do post a comment online or contact the editorial oﬃ  ce if 
you have suggestions for what developments you would 
like to see. Th ank you, as ever, to our editorial board, 
authors, reviewers, and readers for your support.
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